Yushan × 英博

Moderna8月19日单日上涨177%，市场重估焦点转向肿瘤疫苗的增长与定价空间。INTerpath-001试验显示，个性化疫苗联合Keytruda的无复发生存达统计学显著；但OS、HR及亚组数据未披露，商业化仍取决于4至6周生产与耗材成本。

Andrew Walker × Paul Cerro

Cerro’s HIMS thesis shifts attention from peptide launches to the data and labs layer: subscriber counts have “barely grown” for three quarters, making retention the lever for LTV and payback.The August 10 print will test Eucalyptus-driven revenue upside against lower EBITDA guidance, the first full Novo Nordisk partnership quarter, and execution by management Cerro says he does not trust.

Peter Diamandis × Emad Mostaque × Dave Blundin × Dr. Alexander Wissner-Gross

Anthropic’s confidential IPO could make frontier AI a public-market asset class; Polymarket assigns a 60% chance of valuation above $1.8 trillion.ChatGPT’s reported one billion monthly users make distribution central as falling intelligence costs intensify the race for each user’s coordinating assistant.Trump’s voluntary 30-day review and DNA-screening debate leave governance unresolved while robotics and longevity attract sovereign-scale capital.

Harry Stebbings × Andrew Dudum

Hims & Hers is down 66% in six months to a $4.35B market cap on over $2.3B of revenue, while Andrew Dudum says weight loss remains one of a dozen clinical categories, not the core business.Its consumer-platform model is reshaping pharmaceutical distribution, using lower-priced GLP-1 access, AI-enabled productivity, and loss-leading diagnostics to build a broader healthcare front door; retention decay remains the key risk to monitor.

Andrew Walker × Judd Arnold

Judd Arnold’s process now favors liquid inflections where small “junior varsity positions” can become large once “people will care,” rather than merely cheap, illiquid stocks.His $TOI thesis is that capitated oncology can redirect prescribing toward lower-cost regimens, with Florida contracts at roughly $35 PMPM versus $3 in California, but clinician control, reimbursement capture, and the post-SPAC SG&A blowout remain execution risks.

Daphne Zohar × Bruce Booth × Eric Schmidt

Biotech’s year-end pause looks like healthy stock-picker consolidation, with XBI near 124 while mediocre data from Pyxis and Nektar were heavily punished.Nearly $9B of October-November follow-ons is creating indigestion, as first-day performance increasingly sets discounts for subsequent deals.Confidential S-1 flips could fuel a Q1 IPO rush, but recycled issuers and a disrupted FDA policy backdrop make quality and execution the key risks.

Dave Ricks

Lilly’s GLP-1 franchise reflects an 18-year compounding bet, with tirzepatide reaching $8.1 billion in Q2 revenue and roughly 20 million prescription users globally as the opportunity expands beyond weight loss.Lilly cut its direct price to $499 and expects an oral drug next year, but reimbursement, patent expiry, R&D funding, biotech distress, and conditional brain-health applications remain key variables.

卫诗婕 × 金星

新氧转向线下医美连锁，以医生、场地、设备和产品调度重建“产业平台”；成熟门店净利率超过10%。近200家“新氧优享”店中店先搭中台，扩张却保持克制；上游投入超10亿元、现金降至11亿元，2026—2027年针剂获证与规模化仍是观察点。

Lukas Biewald × Martin Shkreli

AI’s largest biopharma opportunity may be target selection rather than molecule generation, with an LLM reading roughly 36-38 million PubMed papers to identify overlooked clinical opportunities.BTK illustrates the mechanism: valuable research sat published for 15-20 years, while clinical trials still consume 50-70% of total cost and development cycles approach ten years.Shkreli’s finance suite found millions of dollars in revenue after abandoning forced AI positioning, but breaking-news advantages may diffuse across Wall Street within six months to a year.

Andrew Walker × Adam Patinkin

Lifecore is being repositioned as a pure-play CDMO for sterile fill-finish of complex injectables, where regulatory switching costs and scarce capacity support customer stickiness.The new CEO targets EBITDA margins of at least 25% from roughly 15%, while customer ramp, $150 million of debt, and an 80% probability of change-of-control by 2028 make execution and timing central.